Sunday, October 5, 2008

Bayer's rivaroxaban gets marketing approval in Europe

The European Commission has granted marketing approval for Xarelto (rivaroxaban), a novel anticoagulant taken as one tablet, once-daily, for the prevention of venous blood clots in adult patients undergoing elective (planned) hip or knee replacement surgery.

The details can be read here.

No comments: